Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer
Abraxane in patients with visceral metastases dominant metastatic breast cancer
Metastatic Breast Cancer
DRUG: Abraxane
Progression Free Survival (PFS), 8 weeks
Objective Response Rate (ORR), 8 weeks|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, 8 weeks|Overall Survival (OS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
A Prospective, Single-center, Open-Label, Phase II Study of Abraxane in patients with visceral metastases dominant metastatic breast cancer